The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLVIII.ab

Guillain-Barré (or GB-like) syndrome (w/wo ARF)

Publications

Supakornnumporn S, Katirji B

Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.

Journal of clinical neuromuscular disease 2017 Dec;19;80-83 — 2017 Dec — 80-83

Kelly Wu W, Broman KK, Brownie ER, Kauffmann RM

Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.

Journal of immunotherapy (Hagerstown, Md. : 1997) 2017 06;40;196-199 — 2017 06 — 196-199

Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ

A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.

Journal of immunotherapy (Hagerstown, Md. : 1997) 2013 Jan;36;77-8 — 2013 Jan — 77-8